Editas Medicine, Inc. (0IFK.L)
| Previous close | 5.41 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 5,909 |
| Market cap | 2.822M |
| Beta (5Y monthly) | 2.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.73 |
| Earnings date | 03 May 2024 - 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireEditas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and virtually. The Company is presenting pre-clinical data to support its development of transformative in vivo gene editing medicin
ZacksWhy Is Editas (EDIT) Down 26.2% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GuruFocus.comInsider Sells Shares of Editas Medicine Inc (EDIT)
Editas Medicine Inc (NASDAQ:EDIT), a leading genome editing company, focuses on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world.
